Vneuron Risk and Compliance Voted Best Anti-Money Laundering Compliance Solution Provider in Waters Rankings Awards 2023
17.7.2023 10:00:00 EEST | Business Wire | Press release
Vneuron Risk & Compliance is honored to announce its selection as the "Best AML Compliance Solution Provider'' for 2023 by Waters Rankings Readers and its esteemed clientele. This prestigious recognition stems from the publisher's annual voting, solidifying Vneuron's industry standing.
The twenty-first edition of the Waters Rankings awards competition showcased 35 awards across five categories, including trading services, trading tools, data management, compliance risk management, and infrastructure/connectivity. Each award acknowledges the outstanding global excellence of the ultimate winner.
In the category of Best AML Compliance Solution Provider, Vneuron Risk & Compliance has emerged victorious among 17 nominated global providers, a remarkable feat considering the previous dominance of legacy vendors in this category. This accomplishment underscores Vneuron's dedication to bringing the most advanced technologies for efficiently combating money laundering and terrorism financing on a global scale.
Vneuron has garnered significant recognition in the market following its successful integration of comprehensive regulatory coverage with advanced technologies. This unique approach allows Vneuron to offer automated Know Your Customer (KYC) procedures and screening workflows, along with real-time transaction filtering and AI-powered monitoring. Furthermore, Vneuron provides case management and dynamic investigation capabilities, reinforcing its comprehensive suite of services.
Furthermore, Vneuron addresses the challenge of maintaining compliance while enhancing the customer experience. User-friendly digital portals and self-onboarding tools engage customers throughout the onboarding and review processes, facilitating efficient fulfillment of KYC obligations. Additionally, its process automation engine, integrated into the customer lifecycle platform and KYC component, ensures swift approvals and investigations.
To learn more about Vneuron’s solutions, visit www.vneuron.com
About the Company:
Vneuron, an innovative Anti-Money Laundering (AML) technology provider, designs and implements robust regulatory solutions for over 200 financial institutions across Europe, the Middle East, and Africa. With its headquarters in France, Vneuron is committed to offering customizable solutions tailored to the needs of modern banks as well as non-banking financial institutions, encompassing insurance, capital markets, lending, and FinTech sectors.
About Waters Rankings:
For over two decades, Waters Rankings has provided technology and data insights for the finance industry. With researchers in London, New York, and Hong Kong, the magazine ensures global exposure to financial markets. Through in-depth investigations, readers gain a comprehensive understanding of technology providers.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230714900920/en/
Contact information
For media inquiries, please contact:
Ameni Naimi
press@vneuron.com
For Other inquiries
hello@vneuron.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Mirum Pharmaceuticals and Incyte Announce U.S. FDA Approval of Atebrioz™ (zilurgisertib) for Adult and Pediatric Patients with Fibrodysplasia Ossificans Progressiva26.9.2026 02:00:00 EEST | Press release
Mirum Pharmaceuticals, Inc. (Nasdaq:MIRM) and Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has approved Atebrioz™ (zilurgisertib) tablets to reduce the volume of total new heterotopic ossification (HO) in adult and pediatric patients aged 12 years and older with fibrodysplasia ossificans progressiva (FOP). The recommended dose of Atebrioz is 100 mg administered orally, once daily. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260925436454/en/ “Today marks an important milestone for people living with FOP, bringing a new treatment option to adult and pediatric patients living with this devastating disease,” said Chris Peetz, Chief Executive Officer at Mirum. “At Mirum, we are driven to serve rare disease communities where the unmet need is significant and the opportunity to make a difference is profound. The approval of Atebrioz reflects what can be achieved when industry, researchers
Digital Reef Signs Offtake Agreement with Oreasoc Agriculture to Mitigate the Environmental Footprint of Data Centre Growth Through Rainforest Protection, Appointing Xange.com as Digital MRV Partner25.9.2026 22:19:00 EEST | Press release
At Climate Week NYC, Digital Reef and Oreasoc Agriculture Inc. sign an offtake agreement connecting Digital Reef’s 3.3 GW data centre pipeline with environmental assets exceeding 30 million hectares of South American Amazon rainforest, mitigating the environmental footprint of data centre growth through rainforest protection and restoration where Oreasoc works alongside local communities to protect biodiversity, develop sustainable economies and safeguard their territories. Xange.com are appointed as digital MRV technology partner to monitor the data centres and rainforest where Digital Reef will purchase verified environmental assets generated by Oreasoc, supporting the development of low-carbon data centres mitigating their environmental footprint through the protection of high-integrity natural ecosystems across the South American Amazon, whilst advancing sustainable economic development. AI and data centre demand is driving rapid growth, with the International Energy Agency project
NetApp Announces Intent to Acquire PEAK:AIO to Advance Scalable AI Infrastructure Architecture25.9.2026 16:00:00 EEST | Press release
NetApp® (NASDAQ: NTAP), the intelligent data infrastructure company, today announced its intent to acquire PEAK:AIO, a pioneer in next-generation metadata architecture and high-performance parallel file systems. The planned acquisition is expected to accelerate NetApp's AI infrastructure roadmap by augmenting metadata services and parallel namespace innovation designed to help AI clouds scale shared storage alongside growing GPU clusters. As AI becomes embedded in every enterprise workload, organizations are confronting a new challenge: traditional storage architectures were not designed for the unprecedented scale, concurrency, and performance requirements of AI factories, AI clouds, and next-generation data-intensive applications. NetApp is building an architecture that disaggregates metadata from data and enables metadata services to scale independently, creating a foundation for AI infrastructure capable of supporting trillions of files, exabyte-scale environments, and massively pa
MultiBank Group Secures Two Awards at Forex Expo Dubai 202625.9.2026 15:57:00 EEST | Press release
MultiBank Group, one of the world’s largest financial derivatives institutions, received two awards during its participation at Forex Expo Dubai 2026, held on 22 and 23 September at Dubai World Trade Centre. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260925539591/en/ MultiBank Group was named “Best Global Institutional Financial Ecosystem of the Year” and received the award for “Excellence in Global Financial Markets Innovation and Community Impact.” The Group was named “Best Global Institutional Financial Ecosystem of the Year” and received the award for “Excellence in Global Financial Markets Innovation and Community Impact.” The first award recognised the strength and breadth of MultiBank Group’s global institutional offering, which brings together trading, liquidity, technology, infrastructure, execution, market access and tailored client solutions within an integrated financial ecosystem. The second award acknowledg
Croma-Pharma Introduces saypha ® volume prime Lidocaine25.9.2026 15:04:00 EEST | Press release
Croma-Pharma introduces saypha® volume prime Lidocaine, a cross-linked hyaluronic acid dermal filler that replaces saypha® volume Lidocaine within the company's saypha® portfolio. The new product offers physicians a more versatile solution with expanded indications for both midface volumization and nasolabial folds, backed by strong clinical data. 1,2 saypha® volume prime Lidocaine demonstrated non-inferiority to comparatora in a randomized, subject- and evaluator-blinded, controlled, non-inferiority multicenter, parallel group comparison study with almost 500 patients.2 In the clinical evaluation, a high patient satisfaction highlights improved midface fullness, smoothness and contour, consistent with a rheologic profile designed to provide volumization in the mobile midface.b,2 With saypha® volume prime Lidocaine, Croma-Pharma further strengthens its product range, reflecting the company's long-standing commitment to scientific excellence and continuous product innovation, and provid
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom